Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018 / 임상당뇨병
Journal of Korean Diabetes
; : 6-9, 2019.
Article
de Ko
| WPRIM
| ID: wpr-761472
Bibliothèque responsable:
WPRO
ABSTRACT
In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).”
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Glycémie
/
Maladies cardiovasculaires
/
Comorbidité
/
Soins centrés sur le patient
/
Consensus
/
Diabète
/
Insuffisance rénale chronique
/
Athérosclérose
/
Glucagon-like peptide 1
/
Préférence des patients
Type d'étude:
Guideline
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Journal of Korean Diabetes
Année:
2019
Type:
Article